相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Canrenone on cardiovascular mortality in congestive heart failure CanrenOne eFFects on cardiovascular mortality in patiEnts with congEstIve hearT failure: The COFFEE-IT study
Giuseppe Derosa et al.
PHARMACOLOGICAL RESEARCH (2019)
Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials
Maria-Eleni Alexandrou et al.
JOURNAL OF HYPERTENSION (2019)
The renin-angiotensin system: going beyond the classical paradigms
Robson Augusto Souza Santos et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
George L. Bakris et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
Luis M. Ruilope et al.
AMERICAN JOURNAL OF NEPHROLOGY (2019)
The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure A systematic review and meta-analysis
Hui Pei et al.
MEDICINE (2018)
Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress
Raquel Gonzalez-Blazquez et al.
FRONTIERS IN PHARMACOLOGY (2018)
The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury
Jochen Dutzmann et al.
PLOS ONE (2017)
Efficacy and Safety of Spironolactone in Acute Heart Failure The ATHENA-HF Randomized Clinical Trial
Javed Butler et al.
JAMA CARDIOLOGY (2017)
Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
Seema Patel et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease
Naoki Sato et al.
CIRCULATION JOURNAL (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies
Silvia Lentini et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2016)
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
Gemma Currie et al.
BMC NEPHROLOGY (2016)
Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment
Roland Heinig et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Hypertension Renin-Angiotensin-Aldosterone System Alterations
Luuk te Riet et al.
CIRCULATION RESEARCH (2015)
Nonsteroidal antagonists of the mineralocorticoid receptor
Peter Kolkhof et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Spironolactone for Heart Failure with Preserved Ejection Fraction
Bertram Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial
Katsuyuki Ando et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
The long-term antiproteinuric effect of eplerenone, a selective aldosterone blocker, in patients with non-diabetic chronic kidney disease
Nobuo Tsuboi et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2012)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Regulation of the epithelial sodium channel (ENaC) by membrane trafficking
Michael B. Butterworth
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2010)
Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
Fan Fan Hou et al.
NEPHROLOGY (2010)
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
Sankar D. Navaneethan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Contraceptive Hormone Use and Cardiovascular Disease
Chrisandra L. Shufelt et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: An open-label crossover randomized controlled trial
Leszek Tylicki et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A Randomized controlled study of benazepril and losartan in chronic renal insufficiency
Fan Fan Hou et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease
S. Bianchi et al.
KIDNEY INTERNATIONAL (2006)
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes
Murray Epstein et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy - A randomized, double-masked, cross-over study
K Rossing et al.
DIABETES CARE (2005)
Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile
E Zuhan et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2005)
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease
A Sato et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
Aldosterone: Direct effects on and production by the heart
PC White
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling
JD Stockand et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Effectiveness of aldosterone blockade in patients with diabetic nephropathy
A Sato et al.
HYPERTENSION (2003)
Molecular mechanisms of myocardial remodeling. The role of aldosterone
C Delcayre et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2002)
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
A Chrysostomou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype
M Cicoira et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
分享论文
